Cutia Therapeutics (HK:2487) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics’ CEO and Executive Director, Ms. Zhang Lele, has increased her shareholding in the company, purchasing a total of 28,000 shares in October 2024. This move signals her strong confidence in the company’s future prospects and business outlook. Investors are advised to remain cautious when trading Cutia Therapeutics’ shares.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.